Please check your internet connection and try again.
# MegaCV
## Overview
MegaCV is a combination product containing a statin and ezetimibe, used to lower cholesterol levels.
## Primary Indications
* Primary hyperlipidemia (adjunct to diet)
* Homozygous familial hypercholesterolemia (HoFH)
## Adult Dosing
* **Primary Hyperlipidemia:** 10/20 mg to 80/10 mg once daily.
* Maximum daily dose: 80 mg of the statin component and 10 mg of ezetimibe.
* **HoFH:** 80/10 mg once daily.
## Pediatric Dosing
* **Children 10 years and older:** Dosing is not established for all formulations. Consult specific product labeling or local protocol. Some sources suggest 10 mg/10 mg once daily may be considered in patients requiring higher intensity statin therapy.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. Avoid in patients with active liver disease or unexplained persistent elevations of serum transaminases.
* **Renal Impairment:** No dose adjustment typically required.
## Contraindications
* Active liver disease or unexplained persistent elevations of serum transaminases.
* Hypersensitivity to any component of the drug.
* Pregnancy and breastfeeding.
## Adverse Effects
* **Common:** Myalgia, arthralgia, headache, abdominal pain, diarrhea, nasopharyngitis, upper respiratory tract infection.
* **Serious:** Rhabdomyolysis, myopathy, liver enzyme elevations, angioedema, pancreatitis.
## Key Drug Interactions
* **CYP3A4 Inhibitors (e.g., itraconazole, ketoconazole, clarithromycin):** Increase risk of myopathy and rhabdomyolysis.
* **Fibrates and Niacin:** Increase risk of myopathy and rhabdomyolysis.
* **Cyclosporine:** Increase plasma concentrations of both drugs; use with caution and monitor for adverse effects.
* **Colchicine:** Increased risk of myopathy and rhabdomyolysis.
## Monitoring
* **Baseline:** Lipid panel, liver function tests (ALT, AST).
* **Periodic:** Lipid panel, liver function tests as clinically indicated. Monitor for signs and symptoms of myopathy (muscle pain, tenderness, weakness).
## Clinical Pearls
* MegaCV combines a statin with ezetimibe, providing additive LDL-C lowering.
* The statin component is generally dosed based on its LDL-C lowering goal and patient risk factors.
* Risk of myopathy is increased with higher doses, concomitant use of other lipid-lowering agents (fibrates, niacin), and in patients with risk factors such as advanced age, renal impairment, or hypothyroidism.
***
**Disclaimer:** This information is intended for healthcare professionals. It is essential to consult the most current prescribing information and relevant guidelines for definitive patient management. Dosing may vary based on individual patient factors and local protocols.
